Wuhan General Group is a state of Nevada public corporation that trades on the OTC Market under the ticker symbol ‘’WUHN’’.
Wuhan General Group is an alternative medicinal and botanicals company focused on the application of emerging technologies as well as the clinical research and health application of cannabidiol (CBD)-based medicine to the human and pet care industry for cancer, cardiovascular, mental disorders, chronic pain, and others in Canada, the United States, Europe, and Australia. We are committed to supplying medical grade CBD products, superior patient care while increasing shareholders ROI. We’re on track to achieve a positive cash flow in the first quarter of 2019. According to a new estimate from cannabis industry analysts the Brightfield Group, the CBD market alone could hit $22 billion by 2022.